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ABSTRACT
Objectives: Reimbursement decisions require
evidence of effectiveness and, in general, a blinded
randomised controlled trial (RCT) is the preferred study
design to provide it. However, there are situations
where a cohort study, or even patient series, can be
deemed acceptable. The aim of this study was to
develop an instrument that first examines which study
characteristics of a blinded RCT are necessary, and
then, if particular characteristics are considered
necessary, examines whether these characteristics are
feasible.
Design: We retrospectively studied 22 interventions
from 20 reimbursement reports concerning medical
specialist care made by the Dutch National Health Care
Institute (ZIN) to identify any factors that influenced the
necessity and feasibility of blinded RCTs, and their
constituent study characteristics, that is, blinding,
randomisation and a control group. A literature review
was performed to identify additional factors. Additional
expertise was included by interviewing eight experts in
epidemiology, medicine and ethics. The resulting
instrument was called the FIT instrument (Feasible
Information Trajectory), and was prospectively
validated using three consecutive reimbursement
reports.
Results: (Blinded) RCT evidence was lacking in
5 of 11 positive reimbursement decisions and 3 of
11 negative decisions. In the reimbursement reports,
we found no empirical evidence supporting situations
where a blinded RCT is unnecessary. The literature also
revealed few arguments against the necessity of a
blinded RCT. In contrast, many factors influencing the
feasibility of randomisation, a control group and
blinding, were found in the reimbursement reports and
the literature; for example, when a patient population is
too small or when an intervention is common practice,
randomisation will be hindered.
Conclusions: Policy regarding the necessity and
feasibility of different types of evidence of effectiveness
would benefit from systematic guidance. The FIT
instrument has the potential to support transparent,
reproducible and well-founded decisions on
appropriate evidence of effectiveness in medical
specialist care.
INTRODUCTION
Reimbursement decisions require evidence
of effectiveness. To demonstrate effectiveness,
a blinded randomised controlled trial (RCT)
is, in general, the preferred study design.
The central reimbursement authority in the
Netherlands, the Dutch National Health
Care Institute (ZIN), formerly named Health
Strengths and limitations of this study
▪ In this study, multiple sources were used, includ-
ing 20 reimbursement reports made by the
Dutch National Health Care Institute, along with
literature and expert opinion.
▪ Since most items used to examine which study
characteristics of a blinded randomised con-
trolled trial remain necessary and feasible are
based on general epidemiological principles,
results of this study might also be useful for
reimbursement agencies in countries other than
the Netherlands.
▪ Not all possible study characteristics are taken
into account; the study was limited to the neces-
sity and feasibility of randomisation, a control
group and blinding.
▪ The instrument’s completeness requires further
testing, as does its impact on the decision-
making process in terms of efficiency, reliability
(such as inter/intraobserver reliability) and addi-
tional forms of validity.
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Care Insurance Board (CVZ), applies the principles of
evidence-based medicine (EBM) to determine whether
care is effective.1 EBM is “the conscientious, explicit, and
judicious use of current best evidence in making deci-
sions about the care of individual patients”.2 It integrates
the best available external evidence with individual clin-
ical expertise and patient preferences. In 2015, ZIN will
update its framework for decision-making, and formally
integrate the ‘Grading of Recommendations Assessment,
Development and Evaluation’ (GRADE) system to assess
and grade available evidence.3
Although blinded RCTs are often preferred, they are
not always available, and reimbursement decisions have
to be taken despite suboptimal evidence. A systematic
review by Fischer4 showed that, indeed, the presence of
suboptimal evidence plays an important role in coverage
decision-making. Whereas evidence from RCTs is abso-
lutely necessary to overcome problems such as con-
founding by indication, it has been stressed that, in
some situations, an RCT may be unnecessary, inappro-
priate, impossible or inadequate.5 For example, in situa-
tions where successful interventions for otherwise fatal
conditions become available, an RCT is not required.2
Observational studies may provide valuable information,
in particular on rare or long-term harms,6 but also on
the beneﬁts of an intervention.
The assessment of the quality of available external evi-
dence has received much scientiﬁc attention resulting in
elaborate rating methods such as the GRADE system.7
An assessment of the necessity and feasibility of attaining
certain evidence requirements has, by contrast, received
less attention. The aim of this study was to develop an
instrument that ﬁrst examines which study characteristics
of a blinded RCT are necessary, and then, if particular
characteristics are considered necessary, examines
whether these characteristics are feasible.8 Together, the
necessary and feasible characteristics deﬁne the optimal
study design. A blinded RCT is, by consequence, neces-
sary and feasible when all three characteristics (blinding,
randomisation and a control group) are considered
necessary and feasible. If they are not, a different study
design may be considered optimal.
We focused on evidence of effectiveness for non-
pharmaceutical, therapeutic medical specialist care as a
starting point. Although the instrument is based on this
type of care, it may be applicable to other types of
interventions.
METHODS
Three information sources were used to identify factors
inﬂuencing the necessity and feasibility of different types
of evidence of effectiveness. These sources are speciﬁed
below.
Review of reimbursement reports
All medical specialist care reports published by ZIN
between 1 January 2007 and 31 December 2010 were
collected. Reports were available on all reimbursement
decisions. 1 January 2007 was chosen as a starting point,
since from this date onwards, ZIN ofﬁcially applied the
principles of EBM to determine whether care is effect-
ive. As data extraction was performed in 2011, 2010 was
the last year for which complete reports were available.
A stratiﬁed sample was implemented in order to prevent
ending up with a sample only including reimbursement
reports for which the necessity and feasibility of blinded
RCTs was evident. The reimbursement reports were
therefore classiﬁed into three groups based on their
level of complexity, namely, simple (few necessity or
feasibility issues), intermediate (moderate necessity or
feasibility issues) or complex (complex necessity or feasi-
bility issues), by the three researchers from ZIN ( JH, SK,
IV). Subsequently, a random sample of each group was
drawn (simple N=5, intermediate N=7 and complex
N=8). The resulting sample concerned 22 medical spe-
cialist care interventions (two reports evaluated two
interventions). Then, data from these reports were
extracted in a uniform matter on the following items:
the intervention, the patient group, the reimbursement
decision (negative or positive), the available evidence of
effectiveness, and any arguments that inﬂuenced the
necessity and feasibility of different types of evidence of
effectiveness. A negative or positive reimbursement deci-
sion implies whether the intervention was considered
suitable for reimbursement from the basic health insur-
ance package in the Netherlands. These decisions did
not always rely on the assessment of effectiveness only,
but may take additional reimbursement criteria into
account.
Literature review
A literature review in Medline (1996 to March 2011) was
performed to identify publications that discussed factors
inﬂuencing the necessity and feasibility of different types
of evidence. The Ovid search interface was used. The
search strategy included the following keyword combina-
tions: level? or degree? or criteri$ or hierarch$ or
require$ or assess$ or standard$ and evidence-based
practice. The resulting publications were screened sys-
tematically. Selection on relevance was carried out by
two researchers (SdG, AR). First, titles and abstracts
were screened; publications that might discuss any
factors inﬂuencing the necessity and feasibility of differ-
ent types of evidence of effectiveness were included.
The full texts of the selected publications were then
examined; publications that did not discuss any factors
inﬂuencing the necessity and feasibility of different types
of evidence of effectiveness were excluded, as were pub-
lications not in English and publications not available as
full text. The reference lists of relevant publications were
screened by hand to identify any additional publications
for inclusion. Special attention was given to those factors
affecting the constituent study characteristics of blinded
RCTs; namely, randomisation, a control group and blind-
ing, because there are factors that may inﬂuence one of
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the characteristics but not the other. Each of these
characteristics by itself is meant to reduce bias, hence
the more these characteristics are preserved (up to a
full-blown blinded RCT) the less biased the research
outcomes will be. Obviously, less biased outcomes form
better grounds for decision-making.
Interviews
A draft instrument was drawn based on the factors inﬂu-
encing the necessity and feasibility of different types of
evidence of effectiveness found in the reimbursement
reports and in the literature. Subsequently, additional
expertise was included by interviewing eight experts in
epidemiology, medicine and ethics. All participants were
informed about the purpose and content of the interview
and agreed to participate by email. Interviews were semi-
structured, that is, questions were predeﬁned, but inter-
viewees were allowed to raise other relevant issues not
covered by the interview schedule.9 Seven of eight inter-
views were performed face-to-face, and one was by tele-
phone. The interviews were intended to elicit views and
opinions from respondents on the factors included in
the draft instrument, and to identify additional factors.
Figure 1 shows the steps of the research process,
including its aims.
Definitions of necessity and feasibility
The resulting instrument was called the FIT instrument
(Feasible Information Trajectory). The factors included
were categorised in two groups: The ﬁrst group deals
with the necessity of randomisation, a control group and
blinding, relating to situations in which one or more of
these three characteristic are not required. The second
group deals with the feasibility of randomisation, a
control group and blinding, and was subdivided into two
groups (2A and 2B). Group 2A refers to factors that,
stand alone, are sufﬁciently strong to deviate from ran-
domisation, a control group and/or blinding. Group 2B
refers to factors that, by themselves, are insufﬁciently
strong, but may jointly provide a compelling case to
do so.
Prospective validation
As a last step, the FIT instrument was prospectively vali-
dated by four ZIN decision-makers who were not
involved in the study. They each applied the instrument
on one of three consecutive reimbursement reports
regarding medical specialist care which included
immunotherapy for high-risk neuroblastoma, zygomatic
implants for the atrophic edentulous maxilla and endo-
vascular treatment of complex aortic aneurysms. The
instrument’s face validity was discussed in a joint meeting
with the project team. The main question in this respect
was whether the instrument contained all facets to iden-
tify the necessity and feasibility of the constituent study
characteristics of blinded RCTs. Therefore, the relevance
and clarity of the factors included in the instrument, as
well as the completeness and user-friendliness of the
instrument, were discussed. Instructions about the valid-
ation were sent to the decision-makers beforehand.
These instructions explained the aim of the validation,
and pointed out particular questions to the decision-
makers, such as ‘Do all questions apply?’, ‘Do you miss
any questions?’ and ‘Are the questions clearly stated?’.
Suggestions for improvement of the instrument were
applied if everyone (the decision-makers and the project
team) agreed.
The ﬁnal FIT instrument is programmed in Excel and
requires the user to answer questions regarding the
factors that inﬂuence the necessity and feasibility of ran-
domisation, a control group and blinding.
Since this article does not contain any personal
medical information about an identiﬁable living individ-
ual, ethics approval was not required.
RESULTS
Eleven of 22 reimbursement decisions were negative,
that is, the intervention was not considered suitable for
reimbursement from the basic health insurance package
in the Netherlands, and the remaining 11 decisions were
positive. In 5 of 11 positive reimbursement decisions, evi-
dence from (blinded) RCTs was lacking. Arguments that
contributed to the acceptance of the available evidence
in these cases are presented in table 1. The arguments
listed in the table are the only arguments explicitly men-
tioned in the reimbursement reports.
Of the 11 negative reimbursement decisions, evidence
from (blinded) RCTs was lacking in three of them.
Besides suboptimal evidence of effectiveness, these three
decisions revealed arguments against the acceptance of
Figure 1 Steps of the research process including its aims.
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the available evidence, such as poor quality of the avail-
able evidence and limited evidence on long-term safety
(table 2). The arguments listed in the table are the only
arguments explicitly mentioned in the reimbursement
reports. Apparently, there were no decisive arguments to
accept suboptimal evidence.
In some reimbursement decisions, additional reim-
bursement criteria besides effectiveness were taken into
account. These criteria could have inﬂuenced the reim-
bursement decision, but are not included in table 2.
Evidence from (blinded) RCTs was available in 14 of
22 reimbursement decisions (six positive and eight
negative). Negative decisions were mostly motivated by
the insufﬁcient quality of the RCT, a lack of long-term
evidence, and absence of consensus within the literature
or the profession on the effectiveness and safety of the
intervention. Again, besides effectiveness, other reim-
bursement criteria could have played a role.
The literature search in Medline identiﬁed 98 publica-
tions. Seventy-eight publications were discarded based
on their title or abstract. Additionally, three publications
were excluded, because no full text was available.
Another three publications were excluded, because they
were not written in English. The full texts of the
Table 1 Positive reimbursement decisions in reports with suboptimal evidence of effectiveness; arguments that advocated
for the acceptance of the available suboptimal evidence
Intervention
Arguments that advocated for the acceptance of the available
suboptimal evidence‡
I. Metal on metal (MoM) resurfacing arthroplasty
of the hip for patients with primary or secondary
osteoarthritis*10
▸ Technique has already been used for approximately 10 years
▸ Patients will probably not participate in a randomised study given
the available data
▸ Availability of lower level evidence of effectiveness (comparative
studies, short to medium term)
II. Preimplantation genetic diagnosis (PGD) to
predict β-thalassaemia in second child with
human leucocyte antigen (HLA) typing during
PGD for stem cell transplantation11
▸ PGD as a technique has been proven effective in predicting other
diseases
▸ It is unfeasible to perform comparative studies on the use of PGD to
predict β-thalassaemia
▸ It is unfeasible to perform comparative studies of HLA typing
III. Potassium-titanyl-phosphate (KTP) laser
treatment for patients with lower urinary tract
symptoms (LUTS) caused by benign prostatic
hyperplasia†12
▸ (Double)-blinding is unfeasible in comparing KTP laser treatment with
transurethral resection of the prostate (TURP) for patients with a mildly
enlarged prostate (surgical intervention)
▸ Technique is already frequently used
▸ Patients will probably not participate in a randomised study
▸ No alternative treatment if drugs provide no adequate relief (for
high-risk patients or patients being treated with anticoagulants)
▸ Availability of lower level evidence of effectiveness and safety (only
non-comparative studies for high-risk patients)
IV. Transcatheter pulmonary valve implantation
(TPVI) for patients with an abnormal pulmonary
valve due to a congenital heart defect13
▸ (Double)-blinding is unfeasible in comparing TPVI with surgical
pulmonary valve replacement
▸ Rare condition; only 30 patients are eligible for percutaneous
pulmonary valve implantation in the Netherlands per year
▸ Safety concerns seem limited regarding percutaneous pulmonary
valve implantation, particularly in comparison to open cardiac surgery
▸ Availability of lower level evidence of effectiveness and safety,
case series showed good short-term success rates
V. Proton therapy for patients with intraocular
tumours, chordomas and chondrosarcomas,
and paediatric tumours14
▸ Side effects are rare and mostly happen (many) years later, and the
purpose of the therapy, in particular, is to reduce or prevent late side
effects (instead of to prove effectiveness)
▸ Rare conditions
▸ Technique is already frequently used and there is international
consensus between radiation therapists and oncologists
▸ Availability of lower level evidence of effectiveness (mainly case
series)
*This intervention complied with medical science and medical practice, according to the Dutch National Health Care Institute (ZIN), for
patients with primary or secondary osteoarthritis who failed on conservative treatment, or patients younger than 65 years of age with a
sufficient level of activity. However, in January 2012, this advice was changed in line with the advice of the Netherlands Orthopaedic
Association, based on new national and international published experiences, to not place large-head MoM hip implants and MoM resurfacing
implants.
†This intervention complied with medical science and medical practice, according to ZIN, for patients with a mildly enlarged prostate, high-risk
patients or patients being treated with anticoagulants.
‡Essential arguments are shown in bold.
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remaining 14 publications were examined. Six publica-
tions were excluded since they did not provide any
factors inﬂuencing the necessity and feasibility of differ-
ent types of evidence of effectiveness. The resulting
eight publications revealed overlapping, but also showed
factors in addition to those found in the reimbursement
reports.
Table 3 comprises the ﬁnal FIT instrument, and sum-
marises factors inﬂuencing the necessity and feasibility
of the constituent study characteristics of blinded RCTs,
derived from the reimbursement reports, the literature
review and the interviews.
When is randomisation, a control group or blinding
necessary?
In RCTs, patients are allocated randomly to one of the
interventions being studied, to minimise imbalances in
confounding variables between experimental and
control groups.17–20 The merits of a random allocation
procedure are particularly important if, for example,
confounding by indication is likely. This happens when
the indication for an intervention is related to the
health outcome and, as a result, the effect estimate is
distorted because it is mixed with the effect of a con-
founding variable. A systematic review and meta-analysis
of drug-eluting stents versus bare metal stents showed
that the rates of death and myocardial infarction were
found to be signiﬁcantly reduced with the use of
drug-eluting stents in the observational studies with an
attenuated effect in the RCTs.21 One of the explanations
for this reduction, as mentioned by the authors, was the
non-randomised choice of either drug-eluting stents or
bare metal stents. The decision to use drug-eluting
stents may be based on unmeasured patient character-
istics and may importantly affect subsequent treatment
decisions, including medication use.
A control group for the intervention of interest can
involve placebo, active treatment, no treatment, a different
dose or regimen of the study treatment or external or his-
torical controls.17 A control group is particularly needed if
the disease has a favourable natural history, for example,
when complaints naturally diminish over time.
Uncontrolled or poorly controlled studies tend to overesti-
mate the treatment effect, because they do not take into
account this favourable natural history of the disease.22
Blinding of study participants, health providers and
investigators reduces the risk that knowledge of which
intervention was received, rather than the intervention
itself, affects outcomes.23 Blinding of outcome assessors
combined with a control group is particularly needed if
the primary outcome measure is subjective, such as
quality of life, instead of objective, such as recurrence
from disease or even death.17 20 23 Blinding of patients
and physicians prevents them, for example, from differ-
ential drop-out or differential administration of cointer-
ventions, thereby eliminating possible effects of
differential behaviours across intervention groups.17 20 23
There may, however, be conditions where randomisa-
tion and a control group are not speciﬁcally needed, for
example, in case of a ‘dramatic’ or ‘immediate’ effect,
since it is less likely that the effect will be explained by
(unknown) confounders only.17 19 20 Insulin supplemen-
tation in diabetic patients is an example in which the
effect rapidly follows the intervention. A ‘dramatic’ or
‘immediate’ effect in combination with a plausible rela-
tionship between the pathophysiology of the condition
Table 2 Negative reimbursement decisions in reports with suboptimal evidence of effectiveness; arguments that advocated
against the acceptance of the available evidence
Intervention
Arguments that advocated against the acceptance of the available
evidence†
VI. Transcatheter aortic valve implantation (TAVI)
for patients with aortic valve stenosis*13
▸ Substantial intervention-related mortality, probably (partly) related
to a priori risk profile of study population
▸ No comparative studies available and the quality of the available
evidence is poor (ie, limited duration and limited size)
▸ Randomised controlled trial (RCT) is on-going
VII. Psychoanalysis15 ▸ Insufficient studies (qualitatively adequate) on the effectiveness
available
▸ Existence of several comparative effectiveness studies on long-term
psychoanalytic psychotherapy makes it likely that such studies are
also possible for psychoanalysis
VIII. Breast augmentation with autologous
lipofilling16
▸ Insufficient studies on the effectiveness available (majority are
case reports and non-comparative studies)
▸ No consensus on breast augmentation with autologous lipofilling
(unclear whether possible microcalcifications influence the
assessment of mammograms)
*In October 2011, this advice was changed. In the opinion of the Dutch National Health Care Institute (ZIN), TAVI is care that complies with
established medical science and medical practice for insured persons with severe stenosis of the aortic valve and for whom the surgical risks
are unacceptably high. TAVI belongs in the insured basic package for these insured persons.
†Essential arguments are shown in bold.
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and the mechanism of the intervention may legitimise
suboptimal evidence. Besides plausibility, additional
factors contribute to our belief that the relationship
between an intervention and its effect is indeed causal,
such as consistency (across research settings), temporal-
ity (effect follows treatment) and biological gradient
(dose–response relation).24
When is randomisation, a control group or blinding
hard to achieve?
First, randomisation may be hard to achieve if equipoise
is lacking,25 that is, if there is consensus about the pre-
ferred treatment. In this case, patients and clinicians
would both be unwilling to participate in a randomised
study. Furthermore, ethicists claim that it would be
unethical to randomise patients.26
Second, if outcomes occur in the distant future and
intermediate outcome measures are absent, an extended
follow-up is needed, which complicates randomisa-
tion.17 18 22 27 Also, blinding of patients and physicians
will be problematic, since eventually, for example, physi-
cians may need to know what treatment the patient has
received in deciding on future treatment.
In addition, in case of a small adaptation of an inter-
vention that has already been proven effective and reim-
bursed, randomisation and a control group may also be
hard to achieve. Surgical techniques generally progress
through a number of successive, small modiﬁcations.25
Table 3 Final FIT instrument summarising factors influencing the necessity and feasibility of randomisation, a control group
and blinding
Randomisation?
Control
group?
Blinding of
outcome
assessors?
Blinding of
patients and
physicians?
Reference to
reimbursement
reports
Reference
to the
literature
1. When is randomisation, a control group or blinding necessary?
▸ Confounding by indication + + 17–20
▸ Natural decrease of
symptoms over time
+ 35 22
▸ Subjective outcome
measures
+ + 17 20 23
▸ Differential behaviours
across intervention groups
+ 17 20 23
▸ Dramatic/immediate effects − − 17 19 20
2A. When is randomisation, a control group or blinding hard to achieve?
▸ Lack of equipoise, that is,
consensus about the
preferred treatment
− Report I, III10 12 25 26
▸ Outcomes occur in the
distant future
− − 17 18 22 27
▸ Small adaptation of an
intervention that has
already been proven
effective and reimbursed
− − 25
▸ Extension of the indication
area of a procedure that
has already been proven
effective and reimbursed
− − Report II11
2B. Which factors hinder the feasibility of randomisation, a control group or blinding?
▸ Small patient population − Report IV, V13 14 17 25
▸ Poor prognosis/no
alternative treatment
− − Report III12 29
▸ Intervention is common
practice
− Report I, III,
V10 12 14
25 29
▸ Urgency of the intervention − − 25
▸ Complexity of the
intervention
− − 33 27
▸ Availability of good quality
low level evidence of
effectiveness
− − − − Report I, III, IV,
V10 12–14
A plus sign indicates that randomisation, a control group or blinding is necessary. A minus sign indicates that randomisation, a control group
or blinding is unnecessary, is hard to achieve or is hindered.
FIT, Feasible Information Trajectory.
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Strictly speaking, evidence from RCTs is still required to
demonstrate effectiveness unless there is a minimal
chance that the treatment effect will be poorer than the
effect previously demonstrated. If evidence from RCTs is
required, there are reasons why randomisation and a
control group may be hard to achieve. First, if there is
an imbalance between the amount of effort needed to
provide this evidence and the degree of reduction in
uncertainty about the effectiveness of the intervention,
conducting an RCT will not be very rational. Second, if
RCTs were needed to evaluate each small modiﬁcation,
progress would be slowed.25 Third, excluding half of the
population from the new intervention in order to
reduce a small degree of uncertainty about the treat-
ment effect might not be ethical. If the reimbursement
assessment involves an extension of the indication area
of a procedure that has already been proven effective
and reimbursed for a smaller indication, this may also
legitimise the use of suboptimal evidence.11
Lastly, characteristics of the intervention could make
blinding of the outcome assessors as well as blinding of
patients and physicians impossible. For example, with
most surgical interventions it is impossible to blind the
surgeon. Also, blinding of patients may be impossible, as
was seen in the reimbursement report regarding sacral
neurostimulation in patients with faecal incontinence.
Since this device sends mild electrical pulses to the
sacral nerves that control the bowel and rectum, patients
will feel the treatment they receive, making blinding
impossible.28 When blinding of patients and physicians
is impossible, it still might be possible to blind the
outcome assessors, especially if the intervention is not
visible.
Which factors hinder the feasibility of randomisation,
a control group or blinding?
Besides factors that make randomisation, a control
group or blinding unnecessary or hard to achieve, there
may be several characteristics of the patient population
and the intervention that hinder the feasibility of ran-
domisation, a control group or blinding. Factors that
hinder the feasibility of randomisation, a control group
or blinding may by themselves be insufﬁciently strong,
but may jointly argue for deviating from randomisation,
a control group or blinding.
First, a small patient population limits the feasibility of
an RCT with sufﬁcient power to detect a real effect as
statistically signiﬁcant.17 25 This was suggested in the
reimbursement report on the transcatheter pulmonary
valve implantation and in the reimbursement report on
proton therapy for patients with intraocular tumours,
chordomas and chondrosarcomas and paediatric
tumours.13 14 While international trials are performed to
obtain sufﬁcient power in orphan drug research, per-
forming international trials for non-pharmaceutical
medical specialist care may be complicated, especially
when treatments, such as surgical procedures, vary
across borders.
Second, a poor prognosis in combination with with-
holding the only possibly effective treatment could
hinder the feasibility of randomisation and a control
group, and could therefore legitimatise the acceptance of
suboptimal evidence.29 If treatment is urgent and
patients experience a signiﬁcant burden of the disease
while the new intervention provides the only chance on
improvement, one could argue that it would be unethical
to randomise patients to either doing nothing or the
intervention. This was proposed in appraising the effect-
iveness of KTP laser treatment for high-risk patients with
benign prostatic hyperplasia, since drugs do not always
provide adequate relief for these patients.12
Third, an intervention may be common practice without
the availability of evidence from blinded RCTs.25 29 These
interventions are frequently applied in clinical practice
and sometimes even included in clinical guidelines.
Performing an RCT would be considered as ‘outdated’,
and randomisation would therefore be hindered. Heart,
liver, kidney and lung transplantations are examples of
interventions that are not validated with RCTs.30 This argu-
ment was also mentioned in the reimbursement reports
on metal on metal resurfacing arthroplasty, treatment with
KTP laser and proton therapy.10 12 14
Fourth, the urgency of an intervention, that is, time
urgency, could hinder randomisation and obtaining
informed consent.25 Fifth, the feasibility of an RCT may
be limited because of the complexity of interventions.27
Complex interventions are generally described as inter-
ventions that contain several interacting components,
but according to Craig et al,31 complex interventions
have some additional characteristics including the
“number and difﬁculty of behaviours required by those
delivering or receiving the intervention, the number of
groups or organisational levels targeted by the interven-
tion, the number and variability of outcomes and the
degree of ﬂexibility or tailoring of the intervention per-
mitted”. The evaluation of a specialist stroke unit is an
example, since such an evaluation would have to con-
sider the expertise of various health professionals as well
as investigations, drugs, treatment guidelines, and
arrangements for discharge and follow-up. Furthermore,
the organisation, management and skill mix of stroke
units differ.32 In the reimbursement report on rheopher-
esis, complexity was put forward to argue that blinding
became unfeasible.33
Lastly, the availability of good quality low level evi-
dence may limit the feasibility of randomisation, a
control group and blinding, since this inﬂuences both
patient and clinical equipoise. Moreover, if this evidence
is methodologically strong, and shows large and consist-
ent results, we may be conﬁdent about the results,34 and
the necessity of randomisation, a control group and
blinding may also be limited.
Prospective validation
During the prospective validation, four ZIN decision-
makers applied the FIT instrument to assess three new
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interventions. In assessing immunotherapy for high-risk
neuroblastoma, the FIT instrument revealed that blind-
ing of outcome assessors, patients and physicians would
be hard to achieve as a result of the characteristics of
the intervention, including its intensity. Although some
factors that hinder randomisation or a control group
were identiﬁed, such as a small patient population and a
poor prognosis, randomisation and a control group were
still considered necessary and feasible. Blinding of
outcome assessors, patients and physicians also appeared
hard to achieve as a result of the characteristics of the
second intervention (zygomatic implants for the atro-
phic edentulous maxilla). Although the FIT instrument
revealed some factors that hinder randomisation and/or
a control group, such as a small patient population and
complexity of the intervention, randomisation and a
control group were still considered necessary and feas-
ible. In assessing endovascular treatment of complex
aortic aneurysms, a small patient population and a poor
prognosis, combined with the absence of an alternative
treatment for some of the patients, were identiﬁed by
the FIT instrument as factors that hinder randomisation
and a control group.
In general, the ZIN decision-makers recognised the
factors included in the instrument and they all found
the instrument useful in deciding what can be consid-
ered the appropriate evidence of effectiveness. Based on
discussions with the decision-makers, two factors hinder-
ing the feasibility of randomisation, a control group or
blinding were excluded: lack of funding and lack of a
good research infrastructure (sufﬁcient expertise, facil-
ities and materials). The reason for these exclusions was
that these factors have an organisational nature, whereas
all other factors relate to characteristics of the patient
population or the intervention. None of the decision-
makers contributed additional factors, the instrument
therefore appeared complete.
DISCUSSION
As reimbursement agencies are under pressure to make
rapid and well-founded decisions on reimbursement,
there is a need for systematic guidance on what can be
considered the appropriate evidence of effectiveness. We
therefore developed an instrument that ﬁrst examines
which study characteristics of a blinded RCT are neces-
sary, and then, if particular characteristics are consid-
ered necessary, examines whether these characteristics
are feasible. As shown in table 3, in the reimbursement
reports we found no empirical evidence supporting
situations where a blinded RCT is unnecessary. The lit-
erature revealed only one situation in which a blinded
RCT was not required, where, in case of a ‘dramatic’ or
‘immediate’ effect, randomisation and a control group
become unnecessary. In contrast, many factors inﬂuen-
cing the feasibility of randomisation, a control group
and blinding were identiﬁed in both the literature and
the reimbursement reports. One could therefore argue
that a blinded RCT is almost always necessary, but not
always feasible.
Recently, Van Loon et al36 considered ﬁve arguments
that limit the feasibility of RCTs in the evaluation of
novel radiotherapy technologies, namely, rare indica-
tions, narrow inclusion criteria, end points that require
data for late toxic effects or second malignant disease,
limited funding and a strong belief in effectiveness of
the novel technique. Additionally, the authors proposed
guidelines for prospective comparative cohort studies
when RCTs are not feasible. The FIT instrument reveals
which study characteristics of a blinded RCT are neces-
sary and feasible resulting in a richer research palette of
study designs that go beyond prospective comparative
cohort studies. For example, differentiation between
controlled observational studies, such as cohort studies,
and observational studies without a control group, is pos-
sible, since the instrument distinguishes between factors
affecting the necessity and feasibility of a control group,
and those affecting the necessity and feasibility of ran-
domisation and blinding. Also, research with a historic
control group may still be possible when, for some
reason, randomisation proved unfeasible.
This study has some limitations. First, in the context of
decision-making, the fundamental question is ‘what to
decide’ given the particular context of an intervention
including the existing evidence. The FIT instrument
does not address this question, but addresses a vital ques-
tion that needs to be answered beforehand, that is, the
FIT instrument examines which study characteristics of a
blinded RCT are necessary, and then, whether these
characteristics are feasible. Thereafter, the appropriate
evidence of effectiveness can be compared with the
actual available evidence. If the available evidence lacks
one or more of the study characteristics that were
deemed necessary, the decision-maker may advise condi-
tional reimbursement, the condition being that further
evidence has to be assembled after reimbursement.
However, the decision-maker may decide not to advise
conditional reimbursement if the explanations for the
existing lack of necessary study characteristics provided
by the FIT instrument are considered legitimate. In this
latter situation, the decision-maker will assume that no
better-ﬁtting evidence will probably appear in the
future, and that a decision based on the available evi-
dence will have to be made. Next to reasons for a sub-
optimal evidence base, additional factors are considered
important in reimbursement decisions, such as disease
severity and budget impact. These latter criteria concern
equity in a given society as well as overall capacity for
reimbursement, and fell beyond the scope of our
research.
The second limitation concerns the instrument’s com-
pleteness. Various disciplines have been active in this
research area, making a complete overview complicated.
Where clinical equipoise originates from ethics, the size
of the patient population is an epidemiological argu-
ment to consider suboptimal evidence. Clinical
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explanations, such as the urgency of an intervention, are
also included in the instrument. Furthermore, there are
practical reasons to deviate from randomisation, a
control group or blinding. Therefore, we do not claim to
have developed a deﬁnitive list of factors to assess the
necessity and feasibility of randomisation, a control
group and blinding. Nevertheless, we have tested the
instrument on three consecutive reimbursement reports
and found, besides its usefulness, that these reports did
not identify any additional arguments. However, we rec-
ommend testing the instrument in future reimburse-
ment decisions and adding any new argument wherever
necessary.
Third, not only does the instrument’s completeness
require further testing, but so does its impact on the
decision-making process in terms of efﬁciency, reliability
(such as inter/intraobserver reliability) and additional
forms of validity. The current validation phase was too
short to properly address these issues. However, regard-
less of its impact on decisions, the instrument provides a
degree of transparency in deﬁning the appropriate evi-
dence for an intervention, and this is in itself an import-
ant improvement over the status quo. The FIT
instrument is frequently used by ZIN decision-makers
since it was made available, which will lead to further
modiﬁcations. ZIN intends to examine the FIT instru-
ment’s validity using the results of its application, and
also intends to compare the results of its application to
the available evidence for the interventions they have
assessed using the FIT instrument.
Fourth, the FIT instrument focuses on the study
characteristics of a blinded RCT, while an RCT has its dis-
advantages, such as limited generalisability and limited
follow-up. Whereas efﬁcacy might be more important for
market authorisation to address causality, effectiveness
might be more important from a decision-making per-
spective, which is the focus of this study. The optimal
study design depends on the outcome of interest. If the
outcome of interest appears to be a safety outcome, a
blinded RCT may no longer be the optimal study design;
the FIT instrument will show that randomisation is hard
to achieve since ‘outcomes occur in the distant future’.
Therefore, the FIT instrument should be used for all out-
comes of interest. Moreover, study design is not the only
criterion to assess the quality of available evidence. This
was pointed out by Guyatt et al,7 who developed the
GRADE system, which ﬁrst qualiﬁes evidence derived
from RCTs as high quality evidence while observational
studies are qualiﬁed as low quality evidence. Conﬁdence
in the estimate of effect is subsequently graded down-
wards and upwards based on criteria such as study limita-
tions and inconsistency of results. For example,
observational studies can be graded upwards if there is
evidence of a dose–response relationship. While the
GRADE approach focuses on assessing the quality of
available evidence, we identiﬁed factors that outline
which types of evidence can, in principle, be available,
thereby providing arguments for reimbursement
decisions when the available evidence does not match
the evidence that is considered necessary and feasible.
Fifth, ﬁndings of this study were partly based on
Dutch reimbursement reports, whereas reimbursement
decisions vary across countries, since they are inﬂuenced
by context, agency process, ability to engage in price
negotiation and, perhaps, differences in social values.37
Since most items in the FIT instrument are based on
general epidemiological principles, the FIT instrument
might be useful for reimbursement agencies in other
countries as well.
Decision-makers strive to attain the most optimal evi-
dence in the assessment of effectiveness, which mostly is
a blinded RCT. There are, however, situations where an
RCT is not speciﬁcally needed, for example, in case of a
‘dramatic’ or ‘immediate’ effect. Furthermore, if an
RCT is needed, as a consequence of ethical as well as
real world practical barriers, combined with the desire
to efﬁciently allocate research funds, the most optimal
evidence might still not be an RCT. Policy regarding the
necessity and feasibility of different types of evidence of
effectiveness would beneﬁt from systematic guidance.
Although the instrument needs further reﬁnement, and
although a critical appraisal of the factors inﬂuencing
the necessity and feasibility of blinded RCTs and its con-
stituent study characteristics remains essential, this
instrument has the potential to support transparent,
reproducible and well-founded decisions on appropriate
evidence of effectiveness in medical specialist care.
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